Univariate analysis for response after infliximab: distribution of responses according to demographic and clinical characteristics
Characteristic . | No. . | No. CR/PR . | % . | P . |
---|---|---|---|---|
Age | .5 | |||
47 y and younger | 10 | 6 | 60 | |
Older than 47 y | 11 | 8 | 73 | |
Sex | .5 | |||
Male | 14 | 10 | 71 | |
Female | 7 | 4 | 57 | |
Acute GVHD grade | .4 | |||
2 | 14 | 10 | 71 | |
3-4 | 4 | 2 | 50 | |
Donor type | .2 | |||
HLA-matched sibling | 11 | 6 | 55 | |
MM rel/MUD | 10 | 8 | 80 |
Characteristic . | No. . | No. CR/PR . | % . | P . |
---|---|---|---|---|
Age | .5 | |||
47 y and younger | 10 | 6 | 60 | |
Older than 47 y | 11 | 8 | 73 | |
Sex | .5 | |||
Male | 14 | 10 | 71 | |
Female | 7 | 4 | 57 | |
Acute GVHD grade | .4 | |||
2 | 14 | 10 | 71 | |
3-4 | 4 | 2 | 50 | |
Donor type | .2 | |||
HLA-matched sibling | 11 | 6 | 55 | |
MM rel/MUD | 10 | 8 | 80 |
MM rel/MUD indicates mismatched related/matched-unrelated donor.